Turning high potential into high performance.

• - Chairman of Places for People
• - Chairman of London & Newcastle
• - Member of Octopus Healthcare Advisory Board
• - Chairman of Horizon Infrastructure Partners
• - Managing Director of PB Securities
• - MD Lombard Odier UK Broking business
• - MD Colliers International UK

• - Founding Director of NCL
• - CIO of Ashberg Ltd
• - Director of funds distribution for NTGI
• - Director at HSBC Securities
• - Director at BoS Investments
• - Holds the IMC, IAQ and is an FCA Approved Person (CF1/CF30)
• - Board positions on various tech SMEs

• - CIO for two technology focused, Family Offices
• - Selection and active Board Membership through to exit of several successful SMEs
• - Founder of high growth health and wellness business
• - EasyGroup new ventures business manager
• - Developer of UKs first reverse auction website
• - Holds an MBA from INSEAD

Mr. O'Neill is an experienced entrepreneurial business owner and corporate executive.

Mr. O'Neill is President of Kent Life Science Fund II, US and a member of the Investment Committee of the Fund. Previously Mr. O'Neill was co-founder and Managing Partner of KOM Capital LLC, a $1.2Bn alternative asset management firm focused on the Life Sciences and early stage energy sectors. Concurrently Mr. O'Neill served as non-executive Chairman of CCF 2, a China focused pre-IPO private equity fund and also has served as non-executive Chairman of SilkRoad China Asset Management LLC, a Hong Kong, investment fund focused on Asian listed securities.

Previously Mr. O'Neill held senior positions as President & Founder, Stewart & Company, a listed institutional asset management firm; Metzler Bank, N.A. as Co-Head, Americas; Canadian Imperial Bank of Commerce ("CIBC") as Managing Director and Senior Vice President, US; and Pitney Bowes Corporation as Controller.
Mr. O'Neill is a graduate of Quinnipiac University and is a Certified Public Accountant (inactive).

• - 35 years as an applied engineer in both pharma and energy sectors
• - Business Manager Technology Centres at National Renewable Energy Centre (now Offshore Renewable Energy Catapult), Program Manager ERDF Inward Investment and Incubation Project
• - Commercialisation Director at PERA, Manager Yorkshire Forward Innovation Practitioner program
• - Business Manager/ Technology Specialist SKF Condition Monitoring/Asset Management Systems
• - Business Manager/Technology Specialist (Pharma process sterile integrity testing) Pall Pharmaceutical
• - Holds a degree in Aerospace systems

• - Ph.D. in Human Genomics from the University of Cambridge
• - Former strategy consultant with 2 of the top 3 European strategy consulting firms
• - Started businesses in the UK and China; incubated and invested in early-stage startups in China
• - Former director at Oxbridge Biotech Roundtable
• - Winner of the Cambridge University Entrepreneurs competition

• - 20 years in Senior Management Commercial and Business Development functions in Pharmaceutical and Biotechnology sector
• - Director of New Product Development & Executive Board Director
• - Launched several small molecule & biologics worldwide
• - 10 years early stage commercialisation experience raising £14m funding (capital, equity, grants)
• - Founder of pre-clinical and regulatory organisation to support early stage therapeutic & medical device commercialisation
• - Commercialisation Advisor to several UK universities

• - CFO at Precision Medicine Catapult Ltd
• - Finance Director at Innovate UK (Managing £650M of government innovation funding).
• - Commercial Director at Firstpoint Healthcare
• - Senior Finance Manager at Vodafone
• - Financial Controller Northern Europe at FedEx

Ms. Jewell Wright is an intern associate in the US office. Ms. Wright is responsible for assisting Mr. O'Neill in Fund administration, investor services, and technical support.

Ms. Wright attends Southern Connecticut State University pursuing a degree in computer science. Additionally she is also a Data Analyst intern in the IBM Watson Analytics program in cognitive analytics. Ms. Wright is a member of the Society of Women Engineers, Golden Key International Honor Society and Secretary off the SCSU Math Club. Ms. Wright holds a Certificate in Electronic Engineering from the Porter & Chester Institute.

Mr. Bell possesses 35 years of corporate finance and management consultancy experience, during which time he has spent over 25 years in the Middle East (GCC ) working on behalf of local and international client base operating across a diverse array of industries. He is founded Bridge Partners in September 2004 as a Strategic Investment Advisory Firm through a network of Pan-Arab business leaders. Bridge Partners has successfully introduced various investment opportunities with a focus on healthcare, clean tech, security and F&B, including innovative funds, direct investments globally and locally, new technologies and innovative businesses to Bridge Partners network for investment. Graham has developed a superior network in the region based on his 25 years in the region, including senior government officials, Royal family members, top executives in the private sector and the heads of the major families in the region with a focus on Saudi Arabia. Previously he was an Associate Partner at PriceWaterhouseCoopers, based in Riyadh and Bahrain responsible for business development, quality control, programme management and the overall management of the Saudi Arabian practice. Mr. Bell has also held senior management positions within Ewbank Preece/Mott Macdonald (Engineering Consultants), InterMatrix (cross border strategy consultants) and Lloyds Bank International.

Jihad A. Fakhreddine is an innovative and highly driven general management professional with more than 30 years of Medical and Pharma experience. He is known for his strong leadership and motivational skills that consistently produce a positive outcome. His expertise in managing International Business Units for JNJ and start-up Medical Devices led to market leadership position for the products launched. His consistent track record of commercialization of start- up in the Middle East and North Africa (MENA) region, with franchises in Diabetes, Oncology, Hepatology and Cardiology that reached multimillion dollar in sales within a couple of years. Jihad’s knowledge in product registration throughout the region is extensive. He managed more than 25 different distributors throughout the Middle East, Africa, and South-Central Asia. All these relationships help introduce products and quick launch.

Jihad’s emphasis on Education, Customer Satisfaction and Health Care Professional accelerate the products intro to the region.

• - 40 years of technology investment experience
• - Founder and Global CEO of Andersen Corporate Finance ($1bn p.a. revenue UK, US, Europe, Asia)
• - CFO and NED in several disruptive technology companies both publicly quoted (UK/USA) and private
• - Former Global Managing Partner of Big 5 firm
• - Former Fellow of ICAEW and Associate Member of Securities Institute
• - BA Hons, First Class, in Business and Finance

• - Currently on the board of several technology SMEs including Starglass SA and Expo Technologies
• - Chairman of Coomtech Ltd
• - 30 years experience managing significant change for international industrial businesses
• - Formerly CEO of Delta plc
• - Formerly Managing Director of GKN Driveline worldwide
• - Has a track record for successfully managing investments through the complete cycle, from identification to exit

• - CEO/MD – Renaissance Capital Partners Ltd (Tech focused innovative company investment fund)
• - CEO/MD – PAD (Property development)
• - Director – Randall & Quilter Investment Holdings PLC ($3Bn under management, Reinsurance, AIM listed)
• - MBA Imperial College (Innovations & Entrepreneurship)
• - CEO – EC3 Solutions Ltd (global reinsurance technology solutions)

President of R&D, CMO at Summit Therapeutics PLC and Chair of Scientific Translation of the Francis Crick Institute. He was head of European R&D for Pfizer. During his tenure at Pfizer and Bayer he was instrumental in the successful development of many important medicines. He was co- founder of the Innovative Medicines Initiative, a two billion Euro public-private partnership. Adviser & NED to a number of Bio-techs and also serves on the Major Awards Committee of the UK’s Biomedical Catalyst Fund. He is a Fellow of the Academy of Medical Sciences.

Director of the Sackler Institute of Pulmonary Pharmacology at King’s College London. Internationally recognized in the pharmacology of inflammatory and respiratory diseases, with over 250 scientific papers. He was the co-founder and former Chairman at Verona Pharma plc (AIM listed), a NED of Babraham Biotechnology, Peptinnovate, Prep Biopharma and Epiendo. He was awarded an OBE for “Services to Pharmacology” in the Queen’s Birthday Honors List in 2017.

Professor of Cancer Therapeutics at University of Kent and Visiting Professor at the Institute of Cancer Research. Previously worked at Onyx Pharmaceuticals developing therapeutic products including the CDK4 inhibitor project, which went onto deliver Ibrance® (Palbociclib). Reader in Cancer Therapeutics and Head of Biology for the CRUK Cancer Therapeutics Unit. Michelle currently has three cancer drugs in the clinic.

Pharma R&D at both Roche and Pfizer. Whilst at Pfizer he helped successfully develop a novel therapy for treatment of HIV infection. Mike also headed up Pfizer’s Opportunities for Partnership in Medicine (OPM) Research Unit and was a member of the Research Leadership Team at Pfizer’s R&D UK Laboratories. Mike is CEO of Centuari Therapeutics and previously Agalimune Ltd.

Martin is the MD of Medway Community Healthcare and Chairman of Albion Outlook, covering 3 regions and over 30,000 patients. Martin joined NHS Medway from Ashford Primary Care Trust. He has a long-standing career in health, which has involved roles in commissioning, primary care and operations.

Co-founder and managing partner of MediqVentures. previously Greg was a managing partner of Palantir Group, Inc. Co-founder of Ascent Healthcare Solutions, VirnetX Inc, Portage Biotech Inc and DuraMedic Inc. He was the initial financier and an independent director of Medivation, Inc. MD and co-Head of Life Sciences at MDB Capital Group LLC